Small cell lung cancer recurrent
Information
- Disease name
- Small cell lung cancer recurrent
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03823118 | Completed | Phase 2 | S1 Plus Anlotinib in Treating Patients With Refractory or Relapsed Small-cell Lung Cancer | March 1, 2019 | April 17, 2021 |
| NCT01441297 | Completed | Phase 2 | BIBF 1120 as Second Line Treatment for Small Cell Lung Cancer | December 2011 | March 31, 2016 |
| NCT06258642 | Not yet recruiting | N/A | Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC | February 2024 | December 2025 |
| NCT03262454 | Recruiting | Phase 2 | Sequential Hypofractionated Radiotherapy Followed by Anti-PD-L1 Atezolizumab for SCLC | January 22, 2018 | July 31, 2024 |
| NCT05815160 | Recruiting | Phase 1 | Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy | May 2, 2023 | April 2026 |
| NCT05027867 | Terminated | Phase 2 | KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer | December 6, 2021 | August 26, 2022 |
| NCT02477813 | Terminated | Phase 2 | Temozolomide in Patients Affected by Relapsed Sensitive or Refractory Small Cell Lung Cancer With MGMT Methylation | January 2015 | June 2018 |
| NCT03994744 | Unknown status | Phase 2 | Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC | August 20, 2019 | July 1, 2022 |